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STATE-OF-THE-ART PAPERS STATE-OF-THE-ART PAPERS1993Nonsustained Ventricular TachycardiaDemosthenes G. Katritsis, Wojciech Zareba, A. John Camm
Non-sustained ventricular tachycardia (NSVT) can be recorded in a wide range of conditions,
from apparently healthy individuals to patients with significant heart disease. In the absence
of heart disease, the prognostic significance of NSVT is debatable. When detected during
exercise, and especially at recovery, NSVT indicates increased cardiovascular mortality within
the next decades. In trained athletes, NSVT is considered benign when suppressed by
exercise. In patients with a non–ST-segment elevation acute coronary syndrome, NSVT
occurring beyond 48 h after admission indicates an increased risk of cardiac and sudden
death, especially when associated with myocardial ischemia. In acute myocardial infarction,
in-hospital NSVT has an adverse prognostic significance when detected beyond the first 13 to
24 h. In patients with prior myocardial infarction treated with reperfusion and beta-blockers,
NSVT is not an independent predictor of long-term mortality when other covariates, such as
left ventricular ejection fraction, are taken into account. In patients with hypertrophic
cardiomyopathy, and most probably genetic channelopathies, NSVT carries prognostic
significance, whereas its independent prognostic ability in ischemic heart failure and dilated
cardiomyopathy is not established. The management of patients with NSVT is aimed at
treating the underlying heart disease.STATE-OF-THE-ART PAPERS2005Risks of Noncardiac Surgery in Patients With Prior PCISandeep Singla, Rajesh Sachdeva, Barry F. Uretsky
Non cardiac surgery may be required within the first year after percutaneous coronary
intervention (PCI) in approximately 4% of patients, and is the second most common reason
for premature discontinuation of antiplatelet therapy. Singla and colleagues provide an
extensive review of published data regarding the risk of perioperative ischemic events,
particularly stent thrombosis, as well as perioperative bleeding and describe strategies to
minimize the risks of adverse outcomes.(continued on page A-22)
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2017Diagnostic Cardiac Catheterization and PCI in the U.S.:
A Report From the CathPCI RegistryGregory J. Dehmer, Douglas Weaver, Matthew T. Roe, Sarah Milford-Beland, Susan Fitzgerald,
Anthony Hermann, John Messenger, Issam Moussa, Kirk Garratt, John Rumsfeld, Ralph G. Brindis
The CathPCI Registry collects data from approximately 85% of the cardiac catheterization
laboratories in the United States. Dehmer and colleagues reviewed data for over 1 million
patients undergoing only diagnostic cardiac catheterization and nearly 1 million undergoing
percutaneous coronary intervention (PCI). Some findings are notable. On-site cardiac surgery
was not available in 83% of facilities performing 200 PCIs annually with these facilities
performing 12% of the PCIs. A total of 39% of those undergoing PCI were 65 years of
age; 12% were 80 years of age. One-half of patients undergoing elective PCI, had a
revious stress study. Radial artery access was used in 8.3% of diagnostic procedures and 6.9%
f PCI procedures. Data from the CathPCI Registry provides a contemporary view of the
urrent practice of invasive cardiology in the United States.ANTIPLATELET THERAPY2032Platelet Reactivity With Reduced Dose Prasugrel in Low Body Weight PatientsDavid Erlinge, Jurrien ten Berg, David Foley, Dominick J. Angiolillo, Henrik Wagner, Patricia B. Brown,
Chunmei Zhou, Junxiang Luo, Joseph A. Jakubowski, Brian Moser, David S. Small, Thomas Bergmeijer,
Stefan James, Kenneth J. Winters
Prasugrel 10-mg is associated with reduced ischemic events compared with clopidogrel
75-mg, but with increased bleeding, particularly in low body weight (LBW) patients. Erlinge
and colleagues hypothesized that prasugrel 5-mg in LBW patients would be noninferior to
prasugrel 10-mg in higher body weight (HBW) patients as assessed by maximal platelet
aggregation (MPA). In this cross-over study in patients with stable CAD on aspirin,
prasugrel 5- and 10-mg and clopidogrel 75-mg were administered to LBW patients (mean
56 kg) and HBW patients (mean 85 kg). Median MPA for prasugrel 5-mg in LBW patients
was similar to that for prasugrel 10-mg in HBW patients. Within LBW patients, prasugrel
5-mg lowered MPA to a greater extent than clopidogrel with lower rates of high on-
treatment platelet reactivity (HPR). These data suggest that a lower dose of prasugrel will be
as effective, and potentially safer, in LBW patients.(continued on page A-23)
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aCARDIOMETABOLIC RISK2041Genetic Inhibition of CETP Results in Reduced Cardiovascular RiskTrine Holm Johannsen, Ruth Frikke-Schmidt, Jesper Schou, Børge G. Nordestgaard, Anne Tybjærg-Hansen
Johannsen and colleagues tested whether genetic variation in cholesteryl ester transfer protein
(CETP) is consistent with a protective effect of CETP inhibition on ischemic risk and total
mortality. The Copenhagen City Heart Study is a prospective cohort study of over 10,000
individuals followed for up to 34 years. Two common genetic variants in CETP previously
associated with reductions in CETP activity were analyzed. In individuals carrying 4 high-
density lipoprotein (HDL) cholesterol-increasing alleles, there was an increase in levels of
HDL cholesterol of up to 14% compared to those with 0 alleles. This was associated with a
hazard ratio of 0.76 for any ischemic vascular event and 0.88 for total mortality. These results
suggest that CETP inhibition is a viable pharmacologic target for reducing cardiovascular risk.Editorial Comment: Sekar Kathiresan, page 2049CARDIOMETABOLIC RISK2053Lp-PLA Bound to HDL is Associated With Lower Cardiovascular Risk2
Loukianos S. Rallidis, Constantinos C. Tellis, John Lekakis, Ioannis Rizos, Christos Varounis,
Athanasios Charalampopoulos, Maria Zolindaki, Nikolaos Dagres, Maria Anastasiou-Nana,
Alexandros D. Tselepis
Plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), which is predominantly
ound to LDL, are associated with the risk of vascular events. However, the role of Lp-
LA2 may depend on the type of lipoprotein to which it is bound. Rallidis and colleagues
examined the prognostic value of high-density lipoprotein (HDL) Lp-PLA2 in patients with
stable coronary artery disease (CAD). Total plasma Lp-PLA2 mass and activity were
predictors of cardiac death after adjustment for traditional risk factors for CAD. In contrast,
HDL-Lp-PLA2 mass and activity were associated with a lower risk of cardiac death after
djustment. These results suggest a complicated role for Lp-PLA2, one that is affected by the
lipoprotein to which it is bound.CARDIOMETABOLIC RISK2061System Review Suggests Benefits for Fibrates in Patients With Kidney DiseaseMin Jun, Bin Zhu, Marcello Tonelli, Meg J. Jardine, Anushka Patel, Bruce Neal, Thaminda Liyanage,
Anthony Keech, Alan Cass, Vlado Perkovic
Fibrate therapy produces modest cardiovascular benefits in people at elevated cardiovascular
risk, but there is limited evidence about the net clinical benefit in patients with chronic
kidney disease (CKD). Jun and colleagues identified 10 prospective, randomized, controlled
trials of fibrate therapy in people with CKD or on kidney-related outcomes. In patients with
mild-moderate CKD (estimated glomerular filtration rate [eGFR] 60), fibrates improved
the lipid profile, with a modest elevation in serum creatinine but no detectable effect on the
risk of end-stage kidney disease. In patients with eGFR 30 to 60, fibrates reduced the risk of
major cardiovascular events and cardiovascular death but not all-cause mortality. These results
suggest that fibrates have a place in reducing cardiovascular risk in patient with CKD.Editorial Comment: Peter A. McCullough, Michael J. Di Loreto, page 2072
(continued on page A-28)
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James D. Thomas, Allan L. Klein
Although left ventricular (LV) global longitudinal strain (GLS) is a sensitive measure of LV
mechanics, its relationship with standard clinical markers and long-term adverse events in
chronic systolic heart failure (HF) is not well established. Motoki and colleagues performed
comprehensive echocardiography with assessment of GLS by vector velocity imaging in
almost 200 patients with chronic systolic HF who were followed for 5 years. GLS correlated
with New York Heart Association functional class, NT-proBNP, and LV ejection fraction
(EF). GLS predicted long-term adverse events and added incremental prognostic value to LV
EF and other clinical predictors.HEART FAILURE
2082Spironolactone Improves Outcomes in Patients With
Severe Heart Failure Regardless of Baseline Kidney FunctionOrly Vardeny, Dong Hong Wu, Akshay Desai, Patrick Rossignol, Faiez Zannad, Bertram Pitt,
Scott D. Solomon
Vardeny and colleagues investigated the influence of baseline and worsening renal function on
the efficacy of spironolactone in patients with severe heart failure (HF) using data from the
RALES trial. In this trial, patients with New York Heart Association functional class III or
IV HF and an ejection fraction 35% were randomized to spironolactone or placebo.
Baseline renal dysfunction was defined as an (eGFR) 60 and worsening renal function
(WRF) as a 30% reduction in eGFR during the first 12 weeks. Individuals with reduced
baseline eGFR exhibited similar relative risk reductions in all-cause death and the combined
endpoint of death or hospitalizations for HF and greater absolute risk reduction compared to
those with a higher baseline eGFR. While WRF was more common with spironolactone, it
did not lead to worse outcomes.
Editorial Comment: Michael S. Kiernan, Marvin A. Konstam, page 2090(continued on page A-29)
NOVEMBER 13, 2012 (continued) A-29HEART RHYTHM DISORDERS2091Propranolol May Be Superior to Other Beta-Blockers for Patients With LQTSPriya Chockalingam, Lia Crotti, Giulia Girardengo, Jonathan N. Johnson, Katy M. Harris,
Jeroen F. van der Heijden, Richard N. W. Hauer, Britt M. Beckmann, Carla Spazzolini, Roberto Rordorf,
Annika Rydberg, Sally-Ann B. Clur, Markus Fischer, Freek van den Heuvel, Stefan Kääb, Nico A. Blom,
Michael J. Ackerman, Peter J. Schwartz, Arthur A. M. Wilde
Beta-blockers (BBs) are the preferred treatment for congenital long QT syndrome
(LQTS), but there are few studies directly comparing the efficacy of commonly-used
BB. Chockalingam and colleagues reviewed electrocardiographic and clinical parameters
of almost 400 LQT1/LQT2 patients initiated on either propranolol, metoprolol, or
nadolol based on clinician or patient preference. The QTc-shortening with propranolol
was significantly greater than with other BBs in the total cohort and particularly in the
subset with QTc 480 ms. There was a greater risk of syncope for symptomatic patients
initiated on metoprolol compared to the other 2 BBs. These results suggest that
propranolol should be the preferred agent for LQTS patients with prolonged QTc,
particularly symptomatic ones.Editorial Comment: James P. Daubert, Augustus O. Grant, Kent R. Nilsson, Jr., page 2100CARDIAC IMAGING2103CCTA as a Gatekeeper to Invasive Diagnostic and Surgical ProceduresLeslee J. Shaw, Jörg Hausleiter, Stephan Achenbach, Mouaz Al-Mallah, Daniel S. Berman,
Matthew J. Budoff, Fillippo Cademartiri, Tracy Q. Callister, Hyuk-Jae Chang, Yong-Jin Kim,
Victor Y. Cheng, Benjamin J. W. Chow, Ricardo C. Cury, Augustin J. Delago, Allison L. Dunning,
Gudrun M. Feuchtner, Martin Hadamitzky, Ronald P. Karlsberg, Philipp A. Kaufmann, Jonathon Leipsic,
Fay Y. Lin, Kavitha M. Chinnaiyan, Erica Maffei, Gilbert L. Raff, Todd C. Villines, Troy LaBounty,
Millie J. Gomez, James K. Min, for the CONFIRM Registry Investigators
The role of coronary computed tomographic angiography (CCTA) in the evaluation of
patients for coronary artery disease (CAD) is still evolving with patterns of follow-up invasive
coronary angiography (ICA) and revascularization after CCTA unknown. The multicenter
CONFIRM registry enrolled over 15,000 intermediate-likelihood patients without known
CAD undergoing CCTA who were followed for 2 years. The results show that patients with
none-mild CAD by CCTA rarely underwent ICA or revascularization. Those with
obstructive CAD by CCTA had higher rates of ICA and revascularization, particularly those
with left main/proximal CAD or higher coronary calcium scores. In exploratory analysis, the
risk of death was higher in patients with mild CAD who underwent ICA, but lower for
patients with CAD by CCTA who underwent ICA. These data support the concept that
CCTA may be effectively used as a gatekeeper to ICA.(continued on page A-30)
NOVEMBER 13, 2012 (continued) A-30CONGENITAL HEART DISEASE
2115In Patients With Fontan Circulation,
SVI Increases During Exercise Due to the Muscle PumpKeri M. Shafer, Jorge A. Garcia, Tony G. Babb, David E. Fixler, Colby R. Ayers, Benjamin D. Levine
In patients with Fontan circulation, it is unclear how venous return is augmented to increase
stroke volume and cardiac output (Qc) during exercise. Shafer and colleagues determined the
relative contribution of the muscle and ventilatory pumps through exercise testing in patients
without a subpulmonic ventricle. The largest increase in stroke volume (SV)/stroke volume
index (SVI) was during unloaded cycling, where the muscle pump is predominant. During
expiratory loading, SVI was reduced to baseline, nonexercise levels in Fontan patients. An
increase in intrathoracic pressure played a deleterious role in Fontan circulation by decreasing
systemic venous return and SV.
